# RETRACTION: Oxaliplatin Activates P53/miR‐34a/Survivin Axis in Inhibiting the Progression of Gastric Cancer Cells

## TL;DR

This retracted study claimed oxaliplatin inhibits gastric cancer by activating a specific molecular pathway, but issues with methodology and data reliability led to its retraction.

## Contribution

The paper originally proposed a novel mechanism involving the P53/miR-34a/Survivin axis in gastric cancer treatment with oxaliplatin.

## Key findings

- Oxaliplatin activates the P53/miR-34a/Survivin pathway in gastric cancer cells.
- This pathway was reported to inhibit cancer progression.
- Results were based on experiments with a contaminated cell line.

## Abstract

RETRACTION: Q. Guo, X.‐Y. Wang, Y.‐C. Zhai, Y.‐W. Dong, and Q.‐S. He, “Oxaliplatin Activates P53/miR‐34a/Survivin Axis in Inhibiting the Progression of Gastric Cancer Cells,” Immunity, Inflammation and Disease 12, no. 9 (2024): e70004, https://doi.org/10.1002/iid3.70004.

The above article, published online on 10 September 2024 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor‐in‐Chief, Marc Veldhoen; and John Wiley & Sons Ltd. The retraction has been agreed upon due to insufficient information included within the methodology, which prevents accurate reproduction of the study. Furthermore, there are concerns that the beta actin bands included in Figure 3a do not originate from the same gel as the other bands shown in this figure. Finally, the cell line used in this study was reported to be contaminated. The authors were contacted for comment and supporting data, but they did not respond. The editors consider the results and conclusions unreliable. The authors were informed of the retraction.